

# Module Two- The biology of cancer

## Overview

Cancer is a complex set of diseases that can arise in any cell of the body capable of evading normal regulatory mechanisms. It typically affects functioning of multiple body systems.

Improvements in understanding the biology of cancer have resulted in substantial changes in its prevention, detection and treatment in recent years. To implement appropriately targeted and evidence based interventions at all stages of the cancer journey, beginning specialist cancer nurses require an understanding of the fundamental concepts associated with the biology and natural history of cancer.

The aim of this module is to develop knowledge of fundamental concepts in cancer care in order for the beginning specialist cancer nurse to demonstrate competence across all domains of practice.

This module focuses specifically on developing an understanding of the fundamental concepts associated with biology of cancer and their implications for nursing practice.

## Key concepts

The key concepts associated with the biology of cancer are listed below:

- Normal cellular growth, proliferation, differentiation and regulatory mechanisms.
- Characteristics of benign and malignant cells and implications for diagnosis and assessment.
- Genetic, immunological and hormonal basis of cancer.
- Processes of invasion and metastasis and implications for diagnosis and assessment.
- Principles of information provision and supportive care during cancer diagnostic processes.
- Common diagnostic processes and investigations for cancer.

## Assumed knowledge and related information

On the basis of your previous education and professional experiences in entry to practice courses or professional development programs, you are expected to understand the fundamentals of:

- human cell structure and function
- cellular components
- the role of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) in protein synthesis
- stressors associated with diagnosis of a serious illness.

## Learning activities

At times, you will have learning activities to complete. The questions will relate to the content you've just read or the video you've just watched.

## Videos

You will be prompted to access EdCaN videos throughout this module.

## Resource links

Resource links may be included throughout the module. These links lead to interesting resources, articles or websites, and are designed to encourage you to explore other available information.

## **Recommended texts**

Access to a current pathophysiology text is recommended to supplement learning and to complete the learning activities within this module. Examples include:

- Tortora, G.J., Derrickson, B. Principles of anatomy & physiology. 13<sup>th</sup> ed. Hoboken: Wiley, 2011.
- Madara, B., Pomarico-Denino, V. Pathophysiology. 2<sup>nd</sup> ed. Sudbury: Jones and Bartlett Publishers, 2008.
- Lazenby, R.B., Corwin, E.J. Handbook of Pathophysiology. 4th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health, 2011.

## **Estimated time to complete**

16 hours

## Learning objectives

On completion of this module, you should be able to:

1. Describe the underlying mechanisms associated with the development of common cancers.
2. Explain the pathophysiological mechanisms underpinning signs and symptoms associated with diagnosis and progression of cancer.
3. Identify strategies to provide information, education and support to people undergoing investigation of symptoms suggestive of cancer.
4. Explain the role of various diagnostic tests for key cancers relevant to clinical populations in your practice setting.

## Normal cell proliferation

Cells form the basic structural and functional units of an organism.<sup>1</sup> All cells contain a cell membrane, cytoplasm and nucleus.<sup>1</sup> Situated in the nucleus is the genetic material or deoxyribonucleic acid (DNA), which is the fundamental building block for life. DNA is made up of subunits called genes. Each gene is coded for a specific product such as a protein or enzyme.<sup>2</sup>

Genes are contained in chromosomes and only the genes required are switched on.<sup>2</sup> Some important genes in the context of cellular proliferation include:

- proto-oncogenes: a gene involved in normal cell growth. Mutations (changes) in a proto-oncogene may cause it to become an oncogene, which can cause the growth of cancer cells.<sup>3</sup>
- tumour suppressor genes (also called antioncogene): a type of gene that makes a protein called a tumour suppressor protein that helps control cell growth. Mutations (changes in DNA) in tumour suppressor genes may lead to cancer.<sup>3</sup>

Each tissue and organ in the body is composed of vast populations of cells, totaling more than  $10^{14}$  (100 000 000 000 000). An astonishing  $10^{12}$  (1 000 000 000 000) cells die or are shed in the normal course of each day and must be replaced to sustain life.

The process by which cells grow and divide to replenish lost cells is termed cell proliferation. This is a highly regulated activity in normal, healthy tissue. The synthesis of new cells is balanced against cell loss so that the total number of cells composing all tissues and organs in the body remains essentially unchanged.<sup>4-7</sup>

Cell growth, the replication of genetic material and cell division are all governed by the cell cycle; a highly-ordered series of events that culminates in mitosis (the division of a cell giving rise to two daughter cells). Progression through the cell cycle depends on successful passage through a number of critical phases – known as checkpoints – which function to ensure the synthesis of fully functioning daughter cells.<sup>6-9</sup> Cell differentiation refers to the process during which young, immature (unspecialized) cells take on individual characteristics and reach their mature (specialized) form and function.<sup>10</sup>

### Learning activities

Completed

Activities

1. Define normal cell proliferation.

2. Outline the phases of the cell cycle and the cellular activities that occur in each of these phases.

3. Identify a cell cycle checkpoint and describe its function.

4. Access [nobelprize.org](http://nobelprize.org) and complete the [Control of the Cell Cycle](#)<sup>11</sup> game.

## Abnormal cell proliferation

While some cell types, such as those that compose the skin and bone marrow, continue to proliferate throughout life, other types including bone and muscle cells cease active proliferation when a human reaches adulthood. Most normal cells remain in a non-proliferative state unless they are stimulated to divide to replace lost cells. Abnormal regulation of the cell cycle can lead to the over proliferation of cells and an accumulation of abnormal cell numbers. Such uncontrolled, abnormal growth of cells is a defining characteristic of cancer.<sup>7, 12, 13</sup>

The total number of cells composing the human body is determined not only by the rate of proliferation of cells but also by the rate of cell loss. Excess cells, and those that are aged or have sustained damage that impairs normal functioning, are eliminated to prevent accumulation of abnormal numbers of cells. The mechanism for regulating the removal of excess and impaired cells is known as apoptosis. Also referred to as cell suicide or programmed cell death, apoptosis is an orderly process during which internal cellular structures are progressively dismantled, the impaired cell shrinks and then is rapidly destroyed by immune cells.<sup>6, 8, 14</sup>

### Role of key genes TP53 and RB1

A number of key genes, proteins and enzymes regulate the cell cycle and the process of apoptosis. Mutations of these key genes affect the action of regulating proteins and enzymes and lead to the loss of regulation of cell proliferation that is seen in cancer. Some cells with mutations evade the apoptosis mechanisms normally responsible for eliminating impaired cells.<sup>4, 6, 7, 12, 14</sup>

Such DNA mutations can result from:

- artificial sources (pesticides, organic chemicals, alkylating agents)
- naturally occurring sources (plant toxins, viruses)
- radiation.

When cell cycle control checkpoints fail, the following may occur:<sup>2</sup>

- the mistake is quickly fixed
- a mutation results in the production of an abnormal protein or enzyme
- a mutation occurs near or around the proto-oncogene turning on cell division when not required
- a mutation occurs near or around tumour suppressor gene (e.g. the p53 gene that normally inhibits the growth of tumours) resulting in inability to stop uncontrolled cell division.

Malignant cells can arise at any stage during the process of differentiation.<sup>15</sup>

## Learning activities

Completed

Activities

1. Describe the key differences between the following types of cell proliferation patterns:
  - anaplasia
  - dysplasia
  - hyperplasia
  - hypertrophy
  - metaplasia.
  
2. Access a current text and/or the [Research Apoptosis web page](#). Explain the role of apoptosis in homeostasis and the development of cancer.
  
3. Outline the characteristics of a 'well differentiated tumour'.

## What is cancer?

Much has changed in our understanding of cancer since Hippocrates, in around 400BC, described a tumour – most likely of breast tissue – as resembling a crab and named it a 'cancer' (which is Latin for crab).

Cancer is not a single disease. It is between 150 and 200 different diseases with a number of common biological properties that identify them as cancer.<sup>5, 16</sup>

Cancer can affect almost any type of cell. Theoretically, therefore, there are as many types of cancer as there are cell types in the human body. Although the location, behaviour and effect of each cancer type may vary, modern advances in biomedical research have identified the biological properties common to all cancer cells that distinguish them from healthy, normal cells. In addition, molecular genetic research has uncovered the role of specific genes and genetic mutations in the transformation of healthy cells to diseased cancer cells.<sup>5, 7, 16-18</sup>

The process by which normal, healthy cells transform into cancer cells is termed carcinogenesis or oncogenesis. The development of a malignant tumour in otherwise healthy tissue is the result of a complex series of events beginning with a single cell that has acquired malignant properties through cellular DNA damage.

Errors in the DNA sequence interrupt the genetic codes that govern the structure and function of the affected cell. The survival and proliferation of a cell with DNA damage, dividing to give rise to two daughter cells each then capable of dividing, eventually results in a population of clones with similar genetic errors and malignant properties.<sup>7, 17, 19</sup>

Before malignant cells can cause symptoms or be detected, successive generations of daughter cells must divide and double the size of the clonal population approximately 30 times. At this point, the tumour will likely measure one cubic centimetre, weigh about one gram and comprise one billion cells.<sup>5, 7</sup>

Most current theories of carcinogenesis characterise it as a multi-step process involving:<sup>7, 9, 14</sup>

- initiation
- growth
- promotion
- conversion
- propagation
- invasion
- metastasis.

Understanding these processes has provided opportunities for development of new therapies targeted at specific steps in this process.

Carcinogens are defined as agents capable of initiating the development of malignant tumours by inducing cellular genetic changes. The transformation of a normal cell to a malignant cell is thought to be due to successive and cumulative exposures to carcinogens and other factors over the course of decades. Most human cancers result from exposure to environmental (or exogenous) carcinogens. Other carcinogens that cause malignant transformation include a broad group of factors from within the body, termed endogenous factors.<sup>6, 19</sup>

## Learning activities

Completed

Activities

1. Summarise the three stage model of carcinogenesis.

2. List two examples each of exogenous and endogenous carcinogens.

3. Provide an explanation of how the carcinogens identified in the previous activity act to initiate the development of a malignant tumour.

## Genetics and cancer

The transformation of normal, healthy cells into diseased cancer cells is directly attributable to genetic damage causing DNA abnormalities that alter cell growth, proliferation and survival.<sup>6, 8, 9</sup> These abnormal genetic changes are termed mutations and may take the form of any of a number of alterations in the DNA sequence of a cell. Mutations may include point mutation, deletion, translocation, and inversion. The eventual impact of a mutation depends on where in the genetic sequence the error occurs.

Increasingly, research is identifying the specific genes and the mutations of the genes that are implicated in the transformation of a normal cell into a cancer cell. The key role played by two groups of cancer genes – proto-oncogenes and tumour suppressor genes – in the malignant transformation of cells is now evident.<sup>6, 7, 9</sup> Examples of such mutations include the up regulation of HER2 in breast cancer, the BCR-ABL translocation in chronic myeloid leukaemia, epidermal growth factor receptor in lung cancer, and C-KIT mutations in gastrointestinal stromal tumours.<sup>20</sup>

Genetic mutations that lead to the malignant transformation of cells and the development of cancer may be acquired or hereditary. Genetic damage resulting from exposure to carcinogens, whether exogenous or endogenous, is classified acquired mutation. Inherited abnormal alterations in the genetic sequence that predispose individuals to cancer are known as hereditary mutations.<sup>6, 8</sup>



## Learning activities

Completed

Activities

- 1. Outline the key differences between hereditary and acquired genetic mutations in the development of cancer.
- 2. Summarise the role of proto-oncogenes and tumour suppressor genes and compare this to the role that their mutated counterparts play in the development of cancer.  
You may find a resource like Cancer Research UK's [How can faulty genes lead to cancer?](#)<sup>21</sup> page helpful for answering this question.
- 3. Watch [Jane's story](#), and complete the following learning activities:



- Discuss how you would explore with Jane her feelings about knowing her mother had 'the gene' and that regular screening did not pick up the diagnosis earlier.
- Identify how the following genes contribute to the development of ovarian cancer and impact on a person's cancer journey:
  - BRCA 1/2
  - HNPCC
- Access [Advice about familial aspects of breast cancer and ovarian cancer: a guide for health professionals](#) and [NCI's Genetics of Breast and Ovarian Cancer](#).
  - Outline issues which may be discussed with Jane's sister Sheila, who is found to carry a BRCA2 mutation, regarding cancer screening and risk reducing strategies.

## Hormones and cancer

Hormones are naturally occurring substances secreted by specialised cells and circulated by blood throughout the body. Hormones act by binding to receptors on the surface of, and influencing the metabolism or behaviour of cells. The normal growth and development of a range of tissues throughout the human body occurs under the influence of hormones.

Excessive hormonal stimulation of cell proliferation increases the risk of mutation and subsequent proliferation of clones of mutated cells. Hormones are therefore capable of acting as powerful carcinogens, and are considered a 'complete carcinogen' because of their ability to both initiate and promote the development of cancers.<sup>4, 6, 7, 19</sup>

Hormones have been implicated in the genesis of breast, prostate, uterine, ovarian, testicular, thyroid and bone cancers. Increased exposure to the hormones oestrogen and progesterone in females has been demonstrated to increase the risk of breast cancer. The early onset of menstruation, late first pregnancy, obesity, late menopause and the use of oral contraceptives all increase the exposure of breast tissue to oestrogen, stimulating increased proliferation. Similarly, the male sex hormone testosterone has been implicated in the development of prostate cancer.<sup>6, 7, 19, 22</sup>

### Learning activity

Completed

Activity

1. Access a current text and summarise the role of hormones in the development of the following cancers:
  - ovarian
  - thyroid
  - prostate.

## The immune system and cancer

An important role in the defense against cancer is surveillance and identification of foreign or 'non-self' substances.<sup>23</sup> Foreign antigens may be exogenous microbes or endogenous altered or virally transformed cells.<sup>24</sup>

The immune system, which recognises foreign micro-organisms as 'non-self' and mounts a response to destroy these disease-causing agents, plays a similar role in protecting the body from malignancy. The damaged DNA in cancer cells frequently directs the mutated cell to produce abnormal proteins known as tumour antigens. These abnormal tumour proteins mark cancer cells as 'non-self'. The immune system likely encounters and eliminates cancer cells on a daily basis. However, it is apparent that cancer cells possess mechanisms that permit them to escape the immune responses that ordinarily prevent the development of malignant tumours.<sup>4, 7, 13, 25, 26</sup>

When the immune system loses its function of surveillance, mutated cells have the ability to form a tumour. Tumour cells that evade detection can be explained by the following proposed mechanisms:<sup>21</sup>

- down regulation of major histocompatibility class (MHC) I expression - allowing antigen to go unrecognised
- lack of co-stimulatory signals needed for antigen presentation - loss or alteration of the MHC molecule
- tumour secretion of immunosuppressive products inhibiting the body's immune response
- tumour being immunogenic by expression of one or more antigens
- antigen modulation - where the antigen either enters the cell or leaves it completely thereby limiting the ability of the immune system to recognise the tumour cell as 'non-self'
- tumours do not give off inflammatory warning signals.

### Learning activities

Completed

Activities

1. Identify the role of the following cells in the immune response to cancer:

- T-lymphocytes
- B-lymphocytes
- natural killer (NK) cells
- macrophages.

2. Describe the ways in which cancer cells evade the immune response.

The immune system can also have a role to play in *treating* cancer. The mechanisms of actions of immunotherapies include:<sup>27</sup>

- enhancement of the individual's immune system
- increasing the vulnerability of cancer cells to the body's immune system
- enhancing the repair of normal cells damaged by treatment.

Immunotherapies currently approved for use in cancer control in Australia include:<sup>28-30</sup>

- cytokines
- cancer vaccines
- tumour-infiltrating lymphocytes
- antibody-activated T cells.

As knowledge of these therapies improves, the categories and application of immunotherapeutic agents will evolve. The large number of agents currently under investigation may be approved for clinical practice. Existing agents may also have application in the treatment of new diagnostic groups and in combination with antineoplastic agents.

#### **Resource link**

A timeline of the progress in the clinical application of targeted therapies is available in [\*Progress in Targeted Therapies for Cancer: Overview\* by Soloman and Zalcbeg](#).<sup>28</sup>

## Cytokines

Cytokines are naturally occurring proteins produced by cells of the immune system (such as lymphocytes and macrophages) that coordinate and initiate effector defence functions.<sup>24</sup> Cytokines include the interleukins, interferons, colony stimulating factors and tumour necrosis factor.

Cytokines can be defined by the following properties:<sup>24</sup>

- they mediate and regulate the immune defense functions by acting as messengers between the various immune cells
- they usually function over short distances and their half-life is brief
- they are produced by a variety of cells types, and can act on diverse cell targets within the immune system and on organs such as the liver
- their actions are both overlapping and contradictory in that they can both stimulate and inhibit growth. In this way, they can act directly or indirectly on a cell causing a cytokine cascade.

Cytokines such as interleukin-2 (IL-2), interferon (IFN), and tumour necrosis factor (TNF) have been used with varying success in the treatment of cancer due to their immunostimulatory effect.

### Learning activities

Completed

Activities

1. Identify an interleukin used in cancer control and describe the:

- mechanism of action
- indications for its use in clinical practice
- nursing care considerations associated with use of this agent.

2. Identify an interferon used in cancer control and describe the:

- mechanism of action
- indications for its use in clinical practice
- nursing care considerations associated with use of this agent.

## **Invasion and metastasis**

A key feature that distinguishes cancer cells from all other cells is their capability to spread throughout the body by two related mechanisms: invasion and metastasis. Advances in our understanding of these processes have provided opportunities for development of new therapies targeted at many of the specific mechanisms described in this section.

### **Invasion**

Invasion refers to the direct extension and penetration by cancer cells into neighbouring tissues. The proliferation of transformed cells and the progressive increase in tumour size eventually leads to a breach in the barriers between tissues. This breach leads to tumour extension into adjacent tissue. Local invasion is also the first stage in the process that leads to the development of secondary tumours or metastases.

### **Metastasis**

Metastasis, from the Greek '*methistanai*' meaning to move to another place, describes the ability of cancer cells to penetrate into lymphatic and blood vessels, circulate through these systems and invade normal tissues elsewhere in the body. This process proceeds in an orderly and predictable manner, sometimes termed the 'metastatic cascade'.<sup>4, 7, 12</sup>

The ability of cancer cells to migrate from a primary site of disease is attributed to the mutation of genes that regulate the production of proteins that normally tether cells to their surrounding tissues. Decreased synthesis by cancer cells of a number of substances that bind them to neighbouring cells, together with the abnormal synthesis of enzymes capable of degrading the bonds between cells and tissues, allow cancer cells to escape the primary tumour site.<sup>4, 7, 12</sup>

### **Angiogenesis**

Angiogenesis has a role in tumour growth, invasiveness and metastasis.<sup>31, 32</sup> Tumour angiogenesis refers to the growth of new vessels which develop following stimulation of endothelial cells within existing vascular networks near the tumour, providing it with a blood supply.<sup>32</sup> A balance of stimulators and inhibitors tightly control angiogenesis under normal circumstances.<sup>2, 24</sup> One specific and potent promoter of angiogenesis is vascular endothelial growth factor (VEGF).<sup>24</sup>

### **Vascular endothelial growth factor (VEGF)**

VEGF is a cytokine which exerts its effects on vascular endothelial cells promoting the formation of new blood vessels and is critical to both normal and tumour angiogenesis.<sup>24, 33</sup> VEGF is over-expressed in a variety of solid tumours and certain hematologic malignancies. VEGF action involves<sup>24</sup>:

- binding to and activating two structurally related membrane receptor tyrosine kinases (TKs)
- switching on of multiple signalling pathways
- stimulating the growth, survival, and proliferation of vascular endothelial cells
- promoting tumour growth and contributing to tumour invasion and metastasis.

### **Tyrosine kinases (TK)**

Tumour growth and progression is further reliant on the activity of specific cell membrane receptors which control signalling pathways within the cell. Cell signalling or 'signal transduction' involves the

communication process where messages or signals from outside the cell are transferred to the nucleus inside the cell.<sup>24</sup> Tyrosine kinases (TK) are a subgroup of growth receptors involved in the signal transduction process.<sup>24</sup> Because TKs are regulators of the signal transduction process, they play a role in cellular processes such as proliferation, migration, metabolism, differentiation and survival.<sup>24</sup> Several important growth factors and other TKs have been identified:<sup>24</sup>

- EGFR family
- platelet derived growth factor receptor (PDGF)
- BCR-ABL
- KIT
- vascular endothelial growth factor (VEGF)
- transforming growth factor
- fibroblast growth factor (FGF).

#### Learning activities

Completed

Activities

1. Access a current text and map the stages of the metastatic cascade, explaining the events in the development of metastases.

2. Access the interactive, animated presentation [\*How Cancer Grows and Spreads\*](#). Discuss how and when such a resource could be used to support the information needs of people affected by cancer.

## Distinguishing benign and malignant growth

The terms 'tumour' and 'neoplasm' are often used interchangeably to describe an abnormal mass of tissue that results from excessive cell proliferation. The term tumour has its origins in the Latin word '*tumere*' meaning 'to swell' and is used to describe an abnormal mass of tissue with no useful bodily function. Neoplasm comes from the Ancient Greek '*neo*' (new) and '*plasma*' (formation) and refers to the pathological formation and growth of abnormal tissue. Both of these terms may be used to describe and classify either a benign or a malignant growth.<sup>7</sup>

### Benign growths

A benign growth does not usually threaten life unless it interferes with vital structures, tissues or organs. Benign growths are generally composed of masses of cells that closely resemble the normal cells that make up the tissue in which they are found. Benign tumours perform no useful bodily function and treatment or removal is usually curative.

### Malignant growths

A malignant growth is composed of cells of atypical structure and function when compared to the healthy cells surrounding them. A malignant tumour, reflecting the Latin origin of the term '*malignans*' meaning to be wicked or to act maliciously, is capable of invading other tissues and, if untreated, usually results in death. Thus, cancer is a malignant disease and the masses of abnormal cells that form a cancer may be termed a malignant tumour or malignant neoplasm.<sup>12, 13</sup>

#### Learning activities

Completed

Activities

1. Access a current text and construct a table that compares and contrasts the characteristics of benign and malignant tumours.

2. Develop an evidence based response for a person affected by a benign brain tumour who asks the following two questions:

- Do I have cancer?
- Seeing as the tumour is not malignant does that mean I will be ok?



## Tumour nomenclature

With the exclusion of hair, teeth and nails, almost any group of cells in the body might become a site for cancer. In order to distinguish cancers, tumours are classified according to the tissue in which they develop.<sup>4, 12, 34</sup>

The human body is composed of two major classes of tissue: parenchymal or epithelial tissues and mesenchymal tissues, comprising connective tissues, muscle and blood vessel. Benign tumours of most tissues are usually simply designated the suffix -oma. Malignant tumours of the parenchyma are designated the term 'carcinoma', while malignant tumours of mesenchymal tissues are designated the term 'sarcoma'.<sup>4, 7, 12</sup>

### Learning activity

Completed

Activity

1. Access a current text and identify the terminology for benign and malignant tumours associated with the following cell types:
  - smooth muscle
  - liver
  - nerve sheath
  - Schwann cells
  - glandular
  - colon
  - blood vessel
  - lung
  - bile duct
  - striated muscle
  - bone.

## Cancer signs and symptoms

The average time between when the initial genetic and cellular changes leading to the development of a cancer occur and the emergence of symptoms related to a tumour is estimated to be as long as 15 to 20 years. During this pre-clinical phase of the development of a cancer, the primary tumour doubles in size as many as 30 times, until it begins to invade and destroy local tissues and organs. It is during this time that clinical symptoms of the tumour become apparent, caused by impairment of normal tissue functioning.<sup>5</sup>

As treatment can be more effective if cancer is detected early, Cancer Council Australia (2009)<sup>35</sup> recommends that individuals get to know their own body and to keep an eye out for any unusual changes such as:

- lumpiness or a thickened area in breasts, any changes in the shape or colour of your breasts, unusual nipple discharge, a nipple that turns inwards (if it hasn't always been that way) or any unusual pain
- a lump in the neck, armpit or anywhere else in the body
- sores or ulcers that don't heal
- coughs or hoarseness that won't go away or coughing up blood
- changes in toilet habits that last more than two weeks; blood in a bowel motion
- new moles or skin spots, or ones that have changed shape, size or colour, or that bleed
- unusual vaginal discharge or bleeding
- unexplained weight loss.

The detection of preclinical signs of some cancers, such as breast, prostate, colorectal and cervical cancers, has given rise to highly effective screening programs that reduce the morbidity and mortality associated with these diseases. More often, however, the presence of worrisome signs and symptoms prompts a visit to a health care professional, in turn leading to diagnosis of a cancer.<sup>36-38</sup>

### Learning activity

Completed

Activity

1. Watch [Harold's story](#), and complete the following learning activity.



- Describe how the signs and symptoms experienced by Harold may be explained by biology associated with the development and progression of lung cancer.

## Diagnosing cancer

The initial evaluation of a person presenting with symptoms suggestive of cancer begins with an assessment of the presenting symptoms, personal and family medical history, risk factors for cancer and a thorough physical examination.

This history and physical examination might suggest an initial diagnosis. However, most often, laboratory tests are performed to confirm the clinician's initial working diagnosis and assist in the evaluation of the impact of a cancer on major organ function. Laboratory studies may include analysis for tumour markers which are helpful in the diagnosis and evaluation of the progress of some cancer types.

The next stage in the diagnostic process generally involves the use of diagnostic imaging techniques to locate the primary tumour and, if indicated, determine the extent of any metastatic disease. Following the localisation of the primary and/or secondary disease sites, the definitive step in establishing a diagnosis is the collection of a tumour tissue sample for pathological analysis. Tissue biopsy for pathological analysis is essential in determining the characteristics of a tumour that will guide decisions about how it should best be treated.<sup>36, 37, 39</sup>

A person who undergoes investigation of symptoms which may be indicative of cancer, or who has a positive screening test which requires further investigation, has particular information and support needs. They are likely to be extremely anxious. Appropriate educative and supportive interventions that respond to these uncertainties and fears will be important.

## Learning activities

Completed

Activities

- 1. Access a current text and summarise the indications, adverse effects and nursing implications for the following methods of obtaining tissue samples for the purpose of making a cancer diagnosis:
  - fine-needle aspiration
  - core needle biopsy
  - excisional biopsy
  - incisional biopsy
  - endoscopic biopsy.
  
- 2. For the following imaging techniques, discuss the indications and their role in cancer diagnosis and preparation required for the procedure:
  - magnetic resonance imaging (MRI)
  - positron emission tomography (PET)
  - x-ray
  - bone scan
  - mammogram.
  
- 3. Watch [\*Johns' story\*](#) and complete the following learning activities:
  - Discuss the potential concerns that John and Carol may have at this time.
  - Access the [\*Clinical practice guidelines for the psychosocial care of adults with cancer\*](#) and outline strategies to:
    - provide support to John and Carol as they respond to a diagnosis of colorectal cancer
    - provide information to respond to questions and clarify John and Carol's understanding of the diagnosis.
  
- 4. Review the records of two individuals in your unit who have recently been diagnosed with cancer, and where possible interview them about their diagnoses. For each person, list the following:
  - procedures used to diagnose their cancer
  - concerns and experiences during the diagnostic phase
  - nursing implications associated with preparing individuals for diagnostic procedures and supporting them during the diagnostic phase.



## References

1. Mautner B, Huang D. Molecular biology and immunology. *Semin Oncol Nurs*. 2003;19(3):154-61.
2. Wilkes GM, Barton-Burke M. 2008 *Oncology Nursing Drug Handbook*. Sudbury: Jones and Bartlett Publishers; 2008.
3. National Cancer Institute. Dictionary. 2009 [20.11.2009]; Available from: [www.cancer.gov/Dictionary/](http://www.cancer.gov/Dictionary/).
4. Blows WT. *The Biological Basis of Nursing: Cancer*. London: Routledge; 2005.
5. Bryan GT, Olsen MR, Robins HI. The natural history and biology of cancer. In: Pollock RE, editor. *Manual of Clinical Oncology*. 7th ed. New York: Wiley-Liss; 1999. p. 1-17.
6. Matakidou A, Eisen T. Genetic basis of cancer. In: Kearney N, Richardson A, editors. *Nursing Patients with Cancer: Principles and Practice*. Edinburgh: Elsevier; 2006. p. 73-95.
7. Van Gerpen R. Pathophysiology. In: Langhorne ME, Fulton JS, Otto SE, editors. *Oncology Nursing* 5th ed. St. Louis: Mosby; 2007. p. 3-16.
8. Rieger P. The biology of cancer genetics *Semin Oncol Nurs*. 2004;20(3):145-54.
9. Rieger PT. Cancer biology and implications for practice. *Clinical Journal of Oncology Nursing*. 2006;10(4):457-60.
10. National Cancer Institute. Dictionary. 2009 [07.12.2011]; Available from: <http://www.cancer.gov/Dictionary/>.
11. AETC National Resource Center. Karnofsky Performance Scale. 2012 [05.07.2012]; Available from: <http://www.aidsetc.org/guide/karnofsky-performance-scale>.
12. Bosman FT. Pathology. In: Kearney N, Richardson A, editors. *Nursing Patients with Cancer: Principles and Practice*. Edinburgh: Elsevier; 2006.
13. Visovsky C, Workman ML. Cancer biology. In: Nevidjon BM, Sowers KW, editors. *A Nurse's Guide to Cancer Care*. Philadelphia: Lippincott; 2000. p. 31-43.
14. Hanahan D, Weinberg RA. The Hallmarks of Cancer. *Cell*. 2000;100:57-70.
15. Fred Hutchison Cancer Research Center. Cell differentiation. 2011 [07.12.2011].
16. International Union Against Cancer. TNM classification: history. 2009 [20.11.2009]; Available from: [http://www.uicc.org/resources/tnm/about.uicc.org/index.php?option=com\\_content&task=view&id=14297&Itemid=429](http://www.uicc.org/resources/tnm/about.uicc.org/index.php?option=com_content&task=view&id=14297&Itemid=429).
17. Sikora K. The molecular basis of cancer. In: Pollock RE, editor. *Manual of Clinical Oncology*. 7th ed. New York: Wiley-Liss; 1999. p. 45-61.
18. National Cancer Institute. Surveillance, Epidemiology and End Results Program home page. 2011 [13.01.2012]; Available from: <http://seer.cancer.gov/>.
19. Vulimiri SV, Digiovanni J. Carcinogenesis. In: Pollock RE, editor. *Manual of Clinical Oncology* 7th ed. New York: Wiley-Liss; 1999. p. 19-43.
20. Bowtell D. Impact of gene technologies on personalised cancer therapy. *Cancer Forum*. 2008;32(3):136-8.
21. O'Connell SA. Complications of Hematopoietic Cell Transplantation. In: Yarbro CH, Frogge M, H., Goodman M, Groenwald SL, editors. *Cancer Nursing Principles and Practice*. 5th ed. Sudbury: Jones and Bartlett Publishers; 2000. p. 523-42.
22. Rennie P, Read J, Murphy L. Hormones and Cancer. In: Tannock F, Hill RP, Bristow RG, Harrington L, editors. *The Basic Science of Oncology*. 4th ed. New York: McGraw-Hill; 2005. p. 400-30.
23. Bauer-Wu SM, Post-White J. Immunology. In: Yarbro CH, Wujcik D, Holmes Gobel B, editors. *Cancer Nursing: Principles and Practice*. Sudbury, MA: Jones & Bartlett; 2011.
24. Battiato L, Wheeler V. Biotherapy. In: Yarbro CH, Wujcik D, Holmes Gobel B, editors. *Cancer Nursing: Principles and Practice*. 5th ed. Sudbury, MA: Jones & Bartlett; 2011.
25. Cancerquest. The immune system. 2008 [20.11.2009]; Available from: <http://www.cancerquest.org/index.cfm?page=2582&lang=english>.

26. Moore JS. The immunological basis of cancer. In: Kearney N, Richardson A, editors. *Nursing Patients with Cancer: Principles and Practice*. Edinburgh: Elsevier; 2006. p. 115-30.
27. Rieger PT. Biotherapy. In: Rieger PT, editor. *Biotherapy: A Comprehensive Overview*. Sudbury: Jones and Bartlett; 2001. p. 3-37.
28. Solomon B, Zalcborg J. Overview: progress in targeted therapies for cancer. *Cancer Forum*. 2008;32:131-5.
29. Polovich M, White JM, Kelleher LO. *Chemotherapy and biotherapy guidelines and recommendations for practice*. 2nd ed. Pittsburgh: Oncology Nursing Society; 2005.
30. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. *Current Opinion in Pharmacology*. [doi: 10.1016/j.coph.2008.06.016]. 2008;8(4):363-9.
31. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. *Nature Clinical Practice Oncology*. 2000;407(6801):249-57.
32. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. *Drugs*. 1999;58(1):17-38.
33. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. *Nature Clinical Practice Oncology*. 2000;407(6801):242-8.
34. Mackillop WJ, Dixon P, Gospodarowicz MK, O'Sullivan B. The role of cancer staging in evidence-based medicine. In: Pollock RE, editor. *Manual of Clinical Oncology*. 7th ed. New York: Wiley-Liss; 1999. p. 215-33.
35. Cancer Council Australia. General advice on early detection. 2009 [20.11.2009]; Available from: <http://www.cancer.org.au/cancersmartlifestyle/Earlydetection/Generaladviceonearlydetection.htm>.
36. Johnson GB. Cancer diagnosis and staging. In: Langhorne ME, Fulton JS, Otto SE, editors. *Oncology Nursing*. 5th ed. St. Louis: Mosby; 2007. p. 70-7.
37. Omerod KF. Diagnostic evaluation, classification, and staging. In: Yarbrow CH, Wujcik D, Holmes Gobel B, editors. *Cancer Nursing: Principles and Practice*. Massachusetts: Jones and Bartlett; 2011.
38. Sloan DA. Screening and early detection. In: Pollock RE, editor. *Manual of Clinical Oncology* 7th ed. New York: Wiley-Liss; 1999. p. 181-99.
39. Geraghty JG, Wobst A. Cancer diagnosis. In: Pollock RE, editor. *Manual of Clinical Oncology*. 7th ed. New York: Wiley-Liss; 1999. p. 201-14.